Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1HRH1HTR7IDH1IDH2IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.88 |
| ▸ | HMGCR | P04035 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | ACLY | P53396 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | SLC13A5 | Q86YT5 | 5/20 | 0.41 |
| ▸ | CPT2 | P23786 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL372127 | 1.00 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL372184 | 1.00 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL372377 | 1.00 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL372650 | 1.00 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL372724 | 1.00 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL372702 | 1.00 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL1410613 | 0.97 | ALDH1A1 (0.83) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL23062790 | 0.97 | ALDH1A1 (0.94) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL11039957 | 0.97 | ALDH1A1 (0.94) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL20607531 | 0.97 | ALDH1A1 (0.94) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 229 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120005447-A | Preparation method of graphene and carbon nanotube composite conductive ink | 浙江浦江永进工贸有限公司 | 2025-05-16 | — | — | CN | claimed |
| US-20250073263-A1 | Method for killing osteosarcoma cells with a bone cement preparation comprising calcium and lithium | Joy Medical Devices Corporation (TW) | 2025-03-06 | — | — | US | claimed |
| CN-119524196-A | Method for killing osteosarcoma cells with a bone cement formulation comprising calcium and lithium | 喜乐医疗器材股份有限公司 | 2025-02-28 | — | — | CN | claimed |
| CN-118610689-B | Preparation method and application of protective layer material capable of inhibiting internal short circuit of lithium battery | 哈尔滨工业大学 | 2025-01-24 | — | — | CN | claimed |
| CN-118754089-B | Preparation method of lithium iron manganese phosphate anode material and lithium battery | 湖南裕能新能源电池材料股份有限公司 | 2024-12-10 | — | — | CN | claimed |
| CN-118754089-A | Preparation method of lithium iron manganese phosphate anode material and lithium battery | 湖南裕能新能源电池材料股份有限公司 | 2024-10-11 | — | — | CN | claimed |
| CN-118610689-A | Preparation method and application of protective layer material capable of inhibiting internal short circuit of lithium battery | 哈尔滨工业大学 | 2024-09-06 | — | — | CN | claimed |
| CN-115093834-B | Phase change material and preparation method and application thereof | 蜂巢能源科技(无锡)有限公司 | 2024-02-27 | — | — | CN | claimed |
| CN-116936784-A | Silicon alloy material, preparation method thereof, silicon anode material and secondary battery | 恒大新能源技术(深圳)有限公司 | 2023-10-24 | — | — | CN | claimed |
| CN-115403288-B | Concrete anticracking agent and its preparation method and use method | 河海大学 | 2023-06-02 | — | — | CN | claimed |
| EP-1838307-A1 | METHODS OF USING TEMOZOLOMIDE FORMULATION INTRATHECALLY IN THE TREATMENT OF CANCERS | SCHERING CORPORATION (US) | 2007-10-03 | — | — | EP | claimed |
| WO-2006060464-A1 | METHODS OF USING TEMOZOLOMIDE FORMULATION INTRATHECALLY IN THE TREATMENT OF CANCERS | SCHERING CORPORATION (US) | 2006-06-08 | — | — | WO | claimed |
| US-20060122162-A1 | Methods of using temozolomide formulation intrathecally in the treatment of cancers | SCHERING CORPORATION | 2006-06-08 | — | — | US | claimed |
| US-6987108-B2 | Pharmaceutical formulations of antineoplastic agents and processes of making and using the same | SCHERING CORPORATION (US) | 2006-01-17 | — | — | US | claimed |
| EP-1478339-A1 | PHARMACEUTICAL FORMULATIONS OF ANTINEOPLASTIC AGENTS, IN PARTICULAR TEMOZOLOMIDE, PROCESSES OF MAKING AND USING THE SAME | SCHERING CORPORATION (US) | 2004-11-24 | — | — | EP | claimed |
| US-20040043001-A1 | Pharmaceutical formulations of antineoplastic agents and processes of making and using the same | SCHERING CORPORATION | 2004-03-04 | — | — | US | claimed |
| WO-2003072082-A1 | PHARMACEUTICAL FORMULATIONS OF ANTINEOPLASTIC AGENTS, IN PARTICULAR TEMOZOLOMIDE, PROCESSES OF MAKING AND USING THE SAME | SCHERING CORPORATION (US) | 2003-09-04 | — | — | WO | claimed |
| EP-0207663-B1 | A METHOD FOR PRODUCING LITHIUM ALUMINATE POWDERS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1989-03-08 | — | — | EP | claimed |
| US-4704266-A | ALUMINUM ALKOXIDE, LITHIUM COMPOUND, WATER, NONAQUEOUS SOLVENT | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1987-11-03 | — | — | US | claimed |
| EP-0207663-A1 | A method for producing lithium aluminate powders | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1987-01-07 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040043001-A1 | Pharmaceutical formulations of antineoplastic agents and processes of making and using the same | ASNS, TP53, QPCTL | MEN1 237/4885ALDH1A1 3247/4885HMGCR 1644/4885 |
| US-20060122162-A1 | Methods of using temozolomide formulation intrathecally in the treatment of cancers | PMP22, TUBB2A, TUBB6 | MEN1 139/4885ALDH1A1 1296/4885HMGCR 2242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.